The firm has opened a $10 million Series A financing round that it expects to close in late summer to support running clinical studies for its assay.
The Access PCT assay can help clinicians assess patients in danger of severe sepsis or septic shock and delivers results in less than 20 minutes.
The company has developed a proof-of-concept single-pore sensor that it anticipates integrating into a prototype testing platform this year.
Since 2017, the companies have been jointly developing an in vitro assay for measurement of sTREM-1 in plasma samples of septic shock patients.
An international group of researchers aim to develop an approach that may be able to diagnose multiple conditions, including pneumonia, tuberculosis, sepsis, with one blood sample.
The new test increases the multiplexing of the sepsis panel from 26 targets to 43 targets, including seven additional resistance genes.
The firm cited continued delays in getting instruments set up and running in labs, leading to less generation of consumables revenues.
The firm said it will use the funds to advance development of its HostDx immune response gene expression tests for acute infections and sepsis.
The firm also announced an exclusive distribution deal covering Israel for its T2 Resistance, T2Bacteria, and T2Candida panels
The startup is exploring options with potential partners and plans to bring a urinary tract infection test through regulatory channels in the next two years.